Joey Lee Methot

USPTO Granted Patents = 32 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 16)

Average Co-Inventor Count = 9.2

ph-index = 6

Forward Citations = 130(Granted Patents)

Company Filing History:

30 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2009-2024

where 'Filed Patents' based on already Granted Patents

32 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12180226 - Spirotricycle RIPK1 inhibitors and methods of uses thereof (2024-12-31),

2. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),

3. 11230547 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2022-01-25),

4. 11179389 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2021-11-23),

5. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-16),

6. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),

7. 10544147 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2020-01-28),

8. 10221178 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2019-03-05),

9. 9938281 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-04-10),

10. 9884048 - ERK inhibitors (2018-02-06),

11. 9730940 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2017-08-15),

12. 9469615 - [object Object] (2016-10-18),

13. 9290453 - [object Object] (2016-03-22),

14. 9233979 - Compounds that are ERK inhibitors (2016-01-12),

15. 9221809 - Aminopyrimidinones as interleukin receptor-associated kinase inhibitors (2015-12-29),

Title: Joey Lee Methot: Innovator in Pharmaceutical Patents

Introduction

Joey Lee Methot is a prolific inventor based in Westwood, MA, holding an impressive portfolio of 32 patents. His contributions to the field of pharmaceutical innovations have garnered attention and respect within the industry, particularly for his work on inhibitors used in the treatment of various diseases.

Latest Patents

Among his recent inventions are the "Spirotricycle RIPK1 inhibitors and methods of uses thereof." This patent details compounds that operate as RIPK1 inhibitors, with the potential to prevent and treat diseases related to RIPK1. The described compounds of Formula I and their pharmaceutically acceptable salts offer new avenues for therapeutic interventions.

Another significant patent of his is the "N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof." This innovation focuses on specific N-heteroaryl indazole derivatives that are effective inhibitors of LRRK2 kinase. As such, they represent promising treatments for diseases such as Parkinson's Disease and other related disorders.

Career Highlights

Joey has built a solid career through his work at notable companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His extensive experience and research endeavors in these prestigious organizations have facilitated his innovative contributions to pharmaceutical sciences.

Collaborations

Throughout his career, Joey has collaborated with talented coworkers, including Hua Zhou and Thomas Allen Miller. These partnerships have allowed for the exchange of ideas and innovations, further enhancing the impact of his research and inventions.

Conclusion

Joey Lee Methot stands out as a key figure in the realm of pharmaceutical patents, particularly with his innovative approaches to treating complex diseases. His patents not only demonstrate his inventiveness but also hold significant promise for future medical breakthroughs. The ongoing pursuit of enhancing healthcare through innovative solutions remains a testament to his dedication and expertise in the field.

This text is generated by artificial intelligence and may not be accurate.